News

Breaking down fat byproducts could lead to healthier aging

Eyleen Jorgelina O’Rourke
By Eyleen Jorgelina O’Rourke
March 17, 2024

The journey of aging brings with it an unavoidable reality for many: an increased accumulation of body fat. Though much of society seems mostly focused on the aesthetics of being overweight, doctors look past any cosmetic concerns to focus on the health implications of fat byproducts in the body.

Fatty acids are one of the molecular building blocks that make up fats. Though essential for various bodily functions, excessive amounts of fatty acids in the body can be harmful, shortening a person’s health span and life span by increasing their risk of chronic disease, disrupting metabolic processes and promoting inflammation.

Fatty acids are routinely checked during medical examinations, such as blood tests measuring your lipid profile. But clinicians and researchers often overlook the other key component of fat despite its potentially harmful effects: glycerol, a compound that links fatty acids to make a fat molecule.

Both of these fat byproducts disrupt cellular and organ function, mirroring the effects of aging. In fact, researchers are increasingly seeing obesity as a catalyst for accelerated aging.

The role that fats play in aging is one of the focuses of my work as a genomicist and biochemist. My research team and I wondered whether reducing harmful fat byproducts might help slow the aging process and consequently stave off common diseases.

Fats perform essential functions in your cells, but not all of them are good for you.

Breaking down fat byproducts

In studying ways to extend the life span and improving the health at late age of lab animals, my colleagues and I saw a consistent pattern: All the anti-aging interventions we tested led to reduced glycerol levels.

For instance, when placed on a calorie-restricted diet, the nematode Caenorhabditis elegans lives about 40% longer. We found that the glycerol levels in the body of these long-lived worms were lower than in shorter-lived worms that were not food restricted. Calorie restriction also heightened the activity of an enzyme responsible for breaking down glycerol, ADH-1, in their intestine and muscles.

We saw similar high ADH-1 activity levels in people undergoing dietary restriction or treated with an anti-aging drug called rapamycin. This finding suggests there may be a common mechanism underlying healthy aging across species, with ADH-1 at its core.

Triacylglycerols, also known as triglycerides, are composed of a glycerol linked to three fatty acids.

We hypothesized that elevated ADH-1 activity promotes health in old age by decreasing harmful levels of glycerol. Supporting this hypothesis were two critical observations. First, we found that adding glycerol to the diet of worms shortened their life span by 30%. By contrast, animals genetically modified to boost levels of the glycerol-busting enzyme ADH-1 had low glycerol levels and remained lean and healthy with longer lives, even on unrestricted diets.

The simple molecular structure and wealth of research on ADH-1 make it an attractive target for developing drugs that boost its activity. My lab’s long-term goal is to explore how compounds that activate ADH-1 affect the health and longevity of both mice and people.

A long-lived society

Anti-aging research generates both excitement and debate. On the one hand, the benefits of healthy aging are clear. On the other hand, extending life span through healthier aging will likely introduce new societal challenges.

If life spans extending to 120 years become the norm, social structures, including retirement ages and economic models, will need to evolve to accommodate an aging population. Legal and social frameworks regarding the elderly and family care may need revision. The sandwich generation, those with children and living parents and grandparents, might find themselves caring for even more generations simultaneously. Longer lives will require society to rethink and reshape how we integrate and support an increasingly older population in our communities.

Whether through ADH-1 or dietary adjustments, the quest for the solution to healthy aging is not just a medical journey but a societal one.The Conversation

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Eyleen Jorgelina O’Rourke
Eyleen Jorgelina O’Rourke

Eyleen Jorgelina O’Rourke is an associate professor of biology and cell biology at the University of Virginia.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Profile

How HCMV hijacks host cells — and beyond

Aug. 12, 2025

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Profile

Understanding the lipid link to gene expression in the nucleus

Aug. 11, 2025

Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.

Receptor antagonist reduces age-related bone loss in mice
Journal News

Receptor antagonist reduces age-related bone loss in mice

Aug. 6, 2025

Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Journal News

Engineered fusion protein targets kiwifruit pathogen

Aug. 6, 2025

Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.